The merger of the two businesses will refocus the company on Health and Nutrition, broaden its pharmaceutical offerings, and boost Roquette’s growth significantly.

IFF, based in New York, USA, is a leading producer of excipients for oral dosage solutions with a global presence, $1B in revenue, and ~1,100 employees. It offers a wide range of quality products to major pharmaceutical, food, and nutraceutical companies worldwide.

Roquette’s acquisition of IFF Pharma Solutions is a game-changer. It strengthens its position in the promising excipients market, boosts its presence in the US, and greatly enhances its formulation capabilities and drug delivery R&D. This move positions Roquette as the preferred partner for innovative drug delivery solutions, meeting customer needs and enhancing patient care.

Roquette and IFF target to close the transaction in the first half of 2025. Closing remains subject to regulatory clearance and satisfaction of other customary closing conditions.